ArticleNucleic acids research2026
The Alteromonas macleodii ribosome enables consecutive incorporation of bulky D-amino acids into peptides.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing ribosomal translation of backbone-altering nonproteinogenic amino acids via YebC and YeeN.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Genetic code reprogramming allows for ribosomal incorporation of exotic amino acids, such as d-α- and d-β-amino acids, into peptides. However, their incorporation efficiency remains much lower than that of canonical l-amino acids, making their multiple/consecutive incorporations difficult. The side chain of d-α-amino acids clashes with U2506 of 23S rRNA, hindering the incorporation of d-α-amino acids with bulky side chains; therefore, consecutive incorporation has been limited to small d-α-amino acids. To overcome this limitation, we screened ribosomes from phylogenetically diverse bacterial species to identify variants that enable consecutive incorporation of bulky d-amino acids. The Alteromonas macleodii (AM) ribosome is capable of incorporating d-α-, d-β-, and α,α-disubstituted amino acids with efficiencies superior to the Escherichia coli (EC) ribosome. It elongates six consecutive d-Ser and two consecutive 1-aminocyclobutane-1-carboxylic acid with yields 6.1- and 7.3-fold higher than the EC ribosome. Moreover, consecutive incorporation of nine types of bulky d-α-amino acids (d-Asn, d-Asp, d-Gln, d-Met, d-Phe, d-Thr, d-Trp, d-Tyr, d-Val) was achieved for the first time. A model macrocyclic peptide containing four d-amino acids and one α,α-disubstituted amino acid was also synthesized by the AM ribosome. These results expand the potential of ribosomal synthesis for peptide libraries containing structurally diverse, bulky d-amino acids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.